Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2023 05:57 ET | Source: The Insight Partners

Breast Cancer Therapeutics Market to Hit $63.96 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners

Pune, India, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Breast cancer is one of the most common types of cancer and has a sizable market for therapies. According to the Centers for Disease Control and...
September 25, 2023 14:45 ET | Source: Zion Market Research

Triple-Negative Breast Cancer Treatment Market Size to Surpass US$ 20 Billion by 2030

NEW YORK, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Triple-Negative Breast Cancer Treatment Market By Drug Type...
July 10, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight

New York, USA, July 10, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight The prevalence of triple-negative breast...
September 29, 2021 16:01 ET | Source: Mountain Valley MD Holdings Inc.

Mountain Valley MD Holdings Provides Business Update, Results of Shareholder Meeting

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to provide a business update on key...
July 13, 2021 09:25 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer

Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne...